Purchase this article with an account.
Piero Fontana, Antonio Fusca, Serena Zanchi; Short term efficacy and safety of intravitreal preservative-free triamcinolone acetonide for the treatment of macular edema. Invest. Ophthalmol. Vis. Sci. 2017;58(8):3694.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
to investigate short term efficacy and safety of intravitreal preservative-free triamcinolone acetonide (IVTA) for the treatment of macular edema in different ocular pathologies. This is a retrospective, observational clinical study to learn about ocular effects after IVTA as first intravitreal therapy
126 eyes of 126 patients (mean age: 71.23 ± 18.23 years) with diabetic macular edema (DME), branch retinal vein occlusion (BRVO) and pseudophakic macular edema (PME) were treated with a single 4mg/0.1 ml IVTA injection and completed a four months follow-up.Outcomes measures were: central macular thickness (CMT), best corrected visual acuity (BCVA), intraocular pressure (IOP) increase and cataract progression.
16 weeks after the IVTA injection, average CMT decreased from baseline 531.31 ± 239.31 µm to 307.26 ± 167.62 µm. Mean decimal BCVA increased from baseline 0.19 ± 0.18 to 0.38 ± 0.33.During the entire follow-up period IOP values over 21 mmHg were measured in 41 (32.5%) patients. In all cases IOP was controlled with topical treatment only.Significant intraocular inflammation did not develop in any patient.Cataract progression was found in 18 (21.4%) of the 84 phakic patients
preservative-free IVTA was effective and relatively safe in the treatment of different groups of macular edema with good temporary beneficial effect on CMT and BCVA
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.
This PDF is available to Subscribers Only